TPCW
RPRX icon

TD Private Client Wealth’s Royalty Pharma RPRX Stock Holding History

TD Private Client Wealth’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.31K Buy
69
+5
+8% +$219 ﹤0.01% 1222
2025
Q4 		$2.47K Buy
64
+15
+31% +$572 ﹤0.01% 1241
2025
Q3 		$1.73K Buy
49
+12
+32% +$434 ﹤0.01% 1260
2025
Q2 		$1.33K Hold
37
– – ﹤0.01% 1268
2025
Q1 		$1.15K Buy
37
+12
+48% +$380 ﹤0.01% 1276
2024
Q4 		$638 Buy
+25
New +$663 ﹤0.01% 1273

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TD Private Client Wealth's RPRX Position: Q1 2026 in Review

TD Private Client Wealth increased its Royalty Pharma (RPRX) stake by 7.8% in Q1 2026, buying an estimated $219 and bringing the position to 69 shares worth $3.31K. The position accounts for ﹤0.01% of the portfolio, ranked #1222.

TD Private Client Wealth first reported a position in RPRX in Q4 2024 and has held it in 6 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • TD Private Client Wealth held 69 shares of Royalty Pharma worth $3.31K as of Q1 2026.
  • TD Private Client Wealth bought 5 Royalty Pharma shares in Q1 2026, an estimated $219.
  • Royalty Pharma made up ﹤0.01% of TD Private Client Wealth's portfolio in Q1 2026, its #1222 holding.
  • TD Private Client Wealth first reported a position in Royalty Pharma in Q4 2024 and has held it in 6 quarters since.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.